M. K. Suleimenov
Research Subjects
M. K. Suleimenov has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Zuriyadda Sakipova
School of Pharmacy, S.D. Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan
4 shared publications - G. S. Ibadullayeva
Asfendiyarov Kazakh National Medical University (KazNMU)
3 shared publications - Ruslan Kulmanbetov
Asfendiyarov Kazakh National Medical University
3 shared publications - A. M. Jakiyanov
Asfendiyarov Kazakh National Medical University
2 shared publications - Tolkyn Bekezhanova
НАО Казахский национальный медицинский униве рситет имени С.Д. Асфендиярова, Алматы, Казахстан
2 shared publications - Zoya B. Allambergenova
School of Pharmacy, S.D. Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan
2 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
Comparative assessment of pharmacopoeial requirements for the quality of raw materials of the genus Linum L.
Introduction. Advancing the standardization framework for medicinal plant raw materials requires greater harmonization of pharmacopoeial specifications and more consistent approaches to quality assessment. Across national pharmacopoeias, quality requirements for raw materials derived from Linum L. species vary with respect to identification criteria, purity parameters, pharmacopoeial quality parameters of the herbal raw material (total ash, acid-insoluble ash, loss on drying, and extractable matter), and the assessment of biologically active constituents. These differences highlight the need to systematize and critically compare the requirements currently in place. Neither Linum pallescens Bunge nor Linum heterosepalum Regel is covered by the pharmacopoeias examined, underscoring the need to establish appropriate quality criteria for these species. The quality parameters and their acceptance criteria for the herbal medicinal raw materials of Linum pallescens Bunge and Linum heterosepalum Regel comply with pharmacopoeial requirements. These species are of particular interest due to the availability of a functioning domestic raw material base, the use of renewable sources of plant material, and the study of their chemical composition for the production of domestic herbal medicinal products. Aim. To conduct a comparative assessment of the pharmacopoeial quality indicators of medicinal plant materials belonging to the genus Linum L. by evaluating pharmacopoeial monographs from different countries and establishing quality specifications for the seeds of Linum pallescens Bunge and Linum heterosepalum Regel. Materials and methods. Pharmacopoeial requirements for the quality assessment of medicinal plant materials belonging to the genus Linum L. were evaluated through a comparative analysis of 13 pharmacopoeias from different countries. Results and discussion. Review of 13 pharmacopoeial monographs revealed the principal quality requirements for medicinal plant materials of the genus Linum L., together with differences in the approaches used for their identification and standardization. A comprehensive quality specification was developed for the seeds of Linum pallescens Bunge and Linum heterosepalum Regel, aimed at expanding the range of pharmacopoeial plant materials and facilitating their use by pharmaceutical manufacturers as plant material for the production of medicinal products. Conclusion. For raw materials derived from plants of the genus Linum L., a comparative assessment of pharmacopoeial quality requirements was conducted; on this basis, a quality specification was developed for Linum pallescens and Linum heterosepalum .
- 6 November 2026
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
Open AccessComparative assessment of pharmacopoeial requirements for the quality of raw materials of the genus Linum L.
Introduction. Advancing the standardization framework for medicinal plant raw materials requires greater harmonization of pharmacopoeial specifications and more consistent approaches to quality assessment. Across national pharmacopoeias, quality requirements for raw materials derived from Linum L. species vary with respect to identification criteria, purity parameters, pharmacopoeial quality parameters of the herbal raw material (total ash, acid-insoluble ash, loss on drying, and extractable matter), and the assessment of biologically active constituents. These differences highlight the need to systematize and critically compare the requirements currently in place. Neither Linum pallescens Bunge nor Linum heterosepalum Regel is covered by the pharmacopoeias examined, underscoring the need to establish appropriate quality criteria for these species. The quality parameters and their acceptance criteria for the herbal medicinal raw materials of Linum pallescens Bunge and Linum heterosepalum Regel comply with pharmacopoeial requirements. These species are of particular interest due to the availability of a functioning domestic raw material base, the use of renewable sources of plant material, and the study of their chemical composition for the production of domestic herbal medicinal products. Aim. To conduct a comparative assessment of the pharmacopoeial quality indicators of medicinal plant materials belonging to the genus Linum L. by evaluating pharmacopoeial monographs from different countries and establishing quality specifications for the seeds of Linum pallescens Bunge and Linum heterosepalum Regel. Materials and methods. Pharmacopoeial requirements for the quality assessment of medicinal plant materials belonging to the genus Linum L. were evaluated through a comparative analysis of 13 pharmacopoeias from different countries. Results and discussion. Review of 13 pharmacopoeial monographs revealed the principal quality requirements for medicinal plant materials of the genus Linum L., together with differences in the approaches used for their identification and standardization. A comprehensive quality specification was developed for the seeds of Linum pallescens Bunge and Linum heterosepalum Regel, aimed at expanding the range of pharmacopoeial plant materials and facilitating their use by pharmaceutical manufacturers as plant material for the production of medicinal products. Conclusion. For raw materials derived from plants of the genus Linum L., a comparative assessment of pharmacopoeial quality requirements was conducted; on this basis, a quality specification was developed for Linum pallescens and Linum heterosepalum .
- Open Access
- 2 March 2026
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 15 (1) , 85-95
Development of the formulation and manufacturing process of lozenges with Ajania fruticulosa (Ledeb.) Poljak dry extract using the Quality by Design concept
Introduction. This article presents the development of a technology for obtaining lozenges containing Ajania fruticulosa dry extract using the direct compression method. The Quality by Design (QbD) concept reflects a modern approach to pharmaceutical development based on the identification and control of Critical Quality Attributes (CQA) and Critical Process Parameters (CPP) that determine their variability. The application of Design of Experiments (DoE) allows for the quantitative assessment of the influence of technological variables and their interactions, optimization of production conditions, reduction of experimental series volume, and ensuring the control of the technological process. Aim. To develop the composition and technology of lozenges with Ajania fruticulosa dry extract using the direct compression method and applying the principles of the QbD concept. Materials and methods. A standardized Ajania fruticulosa dry extract, obtained by maceration with ultrasonic intensification in accordance with the EAEU Pharmacopoeia, was used as the Active Pharmaceutical Ingredient (API). The lozenges were obtained by the direct compression method with varying concentrations of talc (0.1–3.0 %), copovidone (2.0–5.0 %), and compression pressure (15–30 kN). Disintegration time and friability were chosen as the CQAs. Experimental design and statistical analysis were performed using Minitab Statistical Software 22.3.0 (LLC "Minitab", USA) with the DoE module. Disintegration time and friability were determined in accordance with the requirements of the EAEU Pharmacopoeia using ZT 320 and TAR 220 apparatuses (ERWEKA GmbH, Germany). Results and discussion. The optimal API concentration was 1.5 %. According to the DoE results, the copovidone content and compression pressure had a statistically significant effect on the disintegration time, while the contribution of talc was insignificant. The optimal parameters were: copovidone – 5 %, talc – 2 %, compression force – 22 kN. Under these conditions, the disintegration time was 12.9 min, friability was 0.50 %, and the overall desirability index D = 0.8168. Conclusion. The implementation of the QbD concept in combination with DoE provided a scientifically grounded approach to the development of lozenges with Ajania fruticulosa dry extract. The developed lozenges meet the requirements of the EAEU Pharmacopoeia and are recommended for scale-up and industrial production.
- 2 March 2026
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 15 (1) , 85-95
Open AccessDevelopment of the formulation and manufacturing process of lozenges with Ajania fruticulosa (Ledeb.) Poljak dry extract using the Quality by Design concept
Introduction. This article presents the development of a technology for obtaining lozenges containing Ajania fruticulosa dry extract using the direct compression method. The Quality by Design (QbD) concept reflects a modern approach to pharmaceutical development based on the identification and control of Critical Quality Attributes (CQA) and Critical Process Parameters (CPP) that determine their variability. The application of Design of Experiments (DoE) allows for the quantitative assessment of the influence of technological variables and their interactions, optimization of production conditions, reduction of experimental series volume, and ensuring the control of the technological process. Aim. To develop the composition and technology of lozenges with Ajania fruticulosa dry extract using the direct compression method and applying the principles of the QbD concept. Materials and methods. A standardized Ajania fruticulosa dry extract, obtained by maceration with ultrasonic intensification in accordance with the EAEU Pharmacopoeia, was used as the Active Pharmaceutical Ingredient (API). The lozenges were obtained by the direct compression method with varying concentrations of talc (0.1–3.0 %), copovidone (2.0–5.0 %), and compression pressure (15–30 kN). Disintegration time and friability were chosen as the CQAs. Experimental design and statistical analysis were performed using Minitab Statistical Software 22.3.0 (LLC "Minitab", USA) with the DoE module. Disintegration time and friability were determined in accordance with the requirements of the EAEU Pharmacopoeia using ZT 320 and TAR 220 apparatuses (ERWEKA GmbH, Germany). Results and discussion. The optimal API concentration was 1.5 %. According to the DoE results, the copovidone content and compression pressure had a statistically significant effect on the disintegration time, while the contribution of talc was insignificant. The optimal parameters were: copovidone – 5 %, talc – 2 %, compression force – 22 kN. Under these conditions, the disintegration time was 12.9 min, friability was 0.50 %, and the overall desirability index D = 0.8168. Conclusion. The implementation of the QbD concept in combination with DoE provided a scientifically grounded approach to the development of lozenges with Ajania fruticulosa dry extract. The developed lozenges meet the requirements of the EAEU Pharmacopoeia and are recommended for scale-up and industrial production.
- Open Access
- 1 January 2026
- Published by Non-state educational institution "Kazakh-Russian Medical University" in Actual Problems of Theoretical and Clinical Medicine
- No. 3
QUALITY RISK ASSESSMENT OF A DIRECT COMPRESSION TECHNOLOGY FOR LOZENGES CONTAINING AJANIA FRUTICULOSA (LEDEB.) POLJAK EX-TRACT WITHIN THE QUALITY BY DESIGN FRAMEWORK
Relevance. Direct compression enables lozenge manufacturing without wet granulation and drying. However, variability in the properties of herbal extracts may affect the reproducibil-ity of critical quality attributes. Quality risk management within the Quality by Design frame-work supports systematic identification of variability sources and justification of a control strate-gy. Objective. To identify and assess quality risks during the development of a direct com-pression technology for lozenges containing dry Ajania fruticulosa (Ledeb.) Poljak extract. Materials and methods. Potential sources of variability were structured using an Ishika-wa cause-and-effect diagram. Risks were ranked using Failure Mode and Effects Analysis. Se-verity, occurrence, and detectability were assessed using five-point scales, and Risk Priority Numbers (RPNs) were calculated. Residual risks were predicted by expert reassessment of oc-currence and detectability under the proposed mitigation scenario, while severity scores re-mained unchanged. Results. Thirty-six potential variability factors were identified, and seven priority failure modes were selected for Failure Mode and Effects Analysis. Initial RPNs ranged from 18 to 48. Powder blend segregation during feeding into the hopper zone had the highest initial RPN. Un-der the proposed mitigation scenario, predicted residual RPNs ranged from 6 to 24. Six of the seven failure modes were classified as low risk, including five initially classified as medium risk. Powder blend segregation remained a medium risk requiring continued monitoring. Conclusions. The proposed control strategy provides a basis for further process devel-opment, technology transfer, and scale-up. Risk reduction represents an expert prediction and requires experimental confirmation through measurement of the corresponding critical quality attributes.
- 1 January 2026
- Published by Non-state educational institution "Kazakh-Russian Medical University" in Actual Problems of Theoretical and Clinical Medicine
- No. 3
Open AccessQUALITY RISK ASSESSMENT OF A DIRECT COMPRESSION TECHNOLOGY FOR LOZENGES CONTAINING AJANIA FRUTICULOSA (LEDEB.) POLJAK EX-TRACT WITHIN THE QUALITY BY DESIGN FRAMEWORK
Relevance. Direct compression enables lozenge manufacturing without wet granulation and drying. However, variability in the properties of herbal extracts may affect the reproducibil-ity of critical quality attributes. Quality risk management within the Quality by Design frame-work supports systematic identification of variability sources and justification of a control strate-gy. Objective. To identify and assess quality risks during the development of a direct com-pression technology for lozenges containing dry Ajania fruticulosa (Ledeb.) Poljak extract. Materials and methods. Potential sources of variability were structured using an Ishika-wa cause-and-effect diagram. Risks were ranked using Failure Mode and Effects Analysis. Se-verity, occurrence, and detectability were assessed using five-point scales, and Risk Priority Numbers (RPNs) were calculated. Residual risks were predicted by expert reassessment of oc-currence and detectability under the proposed mitigation scenario, while severity scores re-mained unchanged. Results. Thirty-six potential variability factors were identified, and seven priority failure modes were selected for Failure Mode and Effects Analysis. Initial RPNs ranged from 18 to 48. Powder blend segregation during feeding into the hopper zone had the highest initial RPN. Un-der the proposed mitigation scenario, predicted residual RPNs ranged from 6 to 24. Six of the seven failure modes were classified as low risk, including five initially classified as medium risk. Powder blend segregation remained a medium risk requiring continued monitoring. Conclusions. The proposed control strategy provides a basis for further process devel-opment, technology transfer, and scale-up. Risk reduction represents an expert prediction and requires experimental confirmation through measurement of the corresponding critical quality attributes.
- Open Access
- 3 December 2025
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 14 (4) , 208-220
Subacute toxicity, local irritant, and allergenic effects of Hedysarum semenowii extract
Introduction. Hedysarum semenowii Regel & Herder of the genus Hedysarum L., possess a rich phyto-chemical profile and hold promise as a foundation for developing novel pharmaceuticals. Despite the recognized pharmacological activities of various Hedysarum L. species, their safety profiles have not been sufficiently studied, necessitating further investigation to evaluate their toxicity and potential adverse effects. To address this gap, a study was conducted to assess the subacute toxicity, local irritant effects, and allergenicity of Hedysarum semenowii extract, with the aim of determining its safety and therapeutic potential. Aim. Determination of subacute toxicity, local irritant effect and allergenicity of the Hedysarum semenowii Regel & Herder extract. Materials and methods. The subacute toxicity study was performed using outbred rats, with the extract from aerial part of the plant administered orally at doses of 500, 2000, and 5000 mg/kg over a 28-day period. The condition of the animals was monitored throughout the study. At the conclusion of the subacute toxicity evaluation, pathological changes in the liver and kidneys of the experimental animals were examined. Local irritant and allergenic effects were assessed in rats and guinea pigs, respectively, employing visual inspection and the Draize scoring system. Results and discussion. The 28-day subacute toxicity study revealed no significant toxicity, mortality, or behavioral changes in the animals. Body weight, food consumption, and water intake remained stable across all groups. According to the results of macroscopic and microscopic examination, minor physiological changes were noted in the liver and kidneys, the severity of which correlated with the administered doses of the extract. Furthermore, the extract did not induce skin irritation or allergenic reactions in tests involving rats and guinea pigs. Conclusion. Hedysarum semenowii extract exhibited low toxicity and an absence of irritant and allergenic effects, affirming its safety and potential for further exploration as a therapeutic agent.
- 3 December 2025
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 14 (4) , 208-220
Open AccessSubacute toxicity, local irritant, and allergenic effects of Hedysarum semenowii extract
Introduction. Hedysarum semenowii Regel & Herder of the genus Hedysarum L., possess a rich phyto-chemical profile and hold promise as a foundation for developing novel pharmaceuticals. Despite the recognized pharmacological activities of various Hedysarum L. species, their safety profiles have not been sufficiently studied, necessitating further investigation to evaluate their toxicity and potential adverse effects. To address this gap, a study was conducted to assess the subacute toxicity, local irritant effects, and allergenicity of Hedysarum semenowii extract, with the aim of determining its safety and therapeutic potential. Aim. Determination of subacute toxicity, local irritant effect and allergenicity of the Hedysarum semenowii Regel & Herder extract. Materials and methods. The subacute toxicity study was performed using outbred rats, with the extract from aerial part of the plant administered orally at doses of 500, 2000, and 5000 mg/kg over a 28-day period. The condition of the animals was monitored throughout the study. At the conclusion of the subacute toxicity evaluation, pathological changes in the liver and kidneys of the experimental animals were examined. Local irritant and allergenic effects were assessed in rats and guinea pigs, respectively, employing visual inspection and the Draize scoring system. Results and discussion. The 28-day subacute toxicity study revealed no significant toxicity, mortality, or behavioral changes in the animals. Body weight, food consumption, and water intake remained stable across all groups. According to the results of macroscopic and microscopic examination, minor physiological changes were noted in the liver and kidneys, the severity of which correlated with the administered doses of the extract. Furthermore, the extract did not induce skin irritation or allergenic reactions in tests involving rats and guinea pigs. Conclusion. Hedysarum semenowii extract exhibited low toxicity and an absence of irritant and allergenic effects, affirming its safety and potential for further exploration as a therapeutic agent.